Search
Amikacin Inhalation; amikacin liposome inhalation suspension
amikacin liposome inhalation suspension
Indications:
- treatment-resistant Mycobacterium avium complex lung disease
Interactions
drug adverse effects of aminoglycosides
General
amikacin (Amikin)
inhalation agent (inhalant)
References
- FDA News Release. sEPT 28, 2018
FDA approves a new antibacterial drug to treat a serious lung
disease using a novel pathway to spur innovation.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622048.htm